Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07498335 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Not yet
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT07498335: Clinical Trial Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT07498335 is a Phase 3 study that has not yet begun recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07498335, a Phase 3 study, has not yet begun recruiting, sponsored by Novartis Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Primary Outcome
The change in urine protein: creatinine ratio (UPCR) from baseline to Week 36
Interventions
- DRUG Drug: Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-08-26 |
| Est. Completion | 2032-12-13 |
| Phase | Phase 3 |
What is known before NCT07498335 opens enrollment
NCT07498335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Drug: Atrasentan is the first listed.
NCT07498335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07498335 about?
NCT07498335 is a clinical study titled "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN". A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
What is the current status of trial NCT07498335?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2026-08-26. Estimated completion is 2032-12-13.
What interventions are being tested in trial NCT07498335?
The interventions under investigation include: Drug: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT07498335?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07498335's enrollment target sits among peer trials
28 1935th of 2000 higher than 65 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI